194 related articles for article (PubMed ID: 36871027)
1. Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma.
Wang C; Chen Q; Luo H; Chen R
World J Surg Oncol; 2023 Mar; 21(1):76. PubMed ID: 36871027
[TBL] [Abstract][Full Text] [Related]
2. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
3. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
5. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
6. Significance of chromobox protein (CBX) expression in diffuse LBCL.
Hu CY; Li X; Zeng T; Ye DM; Li YK; Yan HX
Gene; 2022 Mar; 813():146092. PubMed ID: 34896523
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma.
Nan YY; Zhang WJ; Huang DH; Li QY; Shi Y; Yang T; Liang XP; Xiao CY; Guo BL; Xiang Y
World J Clin Cases; 2021 Jun; 9(18):4585-4598. PubMed ID: 34222425
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
9. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
10. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.
Peters TL; Li L; Tula-Sanchez AA; Pongtornpipat P; Schatz JH
Oncotarget; 2016 Sep; 7(39):63362-63373. PubMed ID: 27556513
[TBL] [Abstract][Full Text] [Related]
11. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
[TBL] [Abstract][Full Text] [Related]
12. Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.
Luo C; Nie H; Yu L
Oxid Med Cell Longev; 2022; 2022():3334522. PubMed ID: 35069971
[TBL] [Abstract][Full Text] [Related]
13. Analysis of endoplasmic reticulum stress-related gene signature for the prognosis and pattern in diffuse large B cell lymphoma.
Zhang C; Lin Q; Li C; Chen Z; Deng M; Weng H; Zhu X
Sci Rep; 2023 Aug; 13(1):13894. PubMed ID: 37626099
[TBL] [Abstract][Full Text] [Related]
14. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
16. An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma.
Zhou F; Chen L; Lu P; Cao Y; Deng C; Liu G
BMC Cancer; 2023 Jul; 23(1):641. PubMed ID: 37430195
[TBL] [Abstract][Full Text] [Related]
17. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
18. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
[TBL] [Abstract][Full Text] [Related]
19. High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
Liu X; Zhao X; Yang J; Wang H; Piao Y; Wang L
Eur J Haematol; 2023 Feb; 110(2):198-208. PubMed ID: 36335584
[TBL] [Abstract][Full Text] [Related]
20. The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis.
Cristian M; Așchie M; Mitroi AF; Deacu M; Boșoteanu M; Bălțătescu GI; Stoica AG; Nicolau AA; Enciu M; Crețu AM; Caloian AD; Orășanu CI; Poinăreanu I
Medicine (Baltimore); 2024 Feb; 103(6):e36269. PubMed ID: 38335426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]